DNB Markets acted as Financial Adviser in the SEK 160m Private Placement in Vicore Pharma

The offering attracted strong interest from both Nordic and international institutional investors.

On 30 November 2018, Vicore Pharma announced the successful completion of a directed share issue to institutional investors, including HealthCap, Nordic Cross, Fjärde AP-fonden, Handelsbanken Fonder, HBM Healthcare Investments, Alfred Berg, Swedbank Robur and Unionen. 

The offering attracted strong interest from both Nordic and international institutional investors. The subscription price was SEK 17 per share, corresponding to a discount of 4.3% compared to the volume weighted average price 5 days prior to the transaction. 

Vicore Pharma is a Swedish rare disease company focused on interstitial lung diseases and related indications. The proceeds of circa SEK 160m will enable the Company's continued development of the drug development programs VP01 and VP02.

We would like to thank Vicore Pharma for the vote of confidence and wish the company the best of luck going forward.